The Plummet of a Consumer Genetic Testing Pioneer: From $6.5 Billion to Near Zero Market Value

Consumer genetic testing companies, once hailed as the future of personalized healthcare, are facing a harsh reality. In a market fueled by capital frenzy, companies with seemingly attractive business models often enjoy valuations that exceed expectations. One such company, 23andMe, reached a staggering market value of $6.5 billion after going public in 2021. However, in the 2022 fiscal year, the company reported a modest revenue of $272 million and a loss of $217 million. The downfall of 23andMe, a benchmark in consumer genetic testing, raises questions about the future prospects of such companies.

The Rise and Fall of 23andMe:

Consumer genetic testing companies emerged with the ambition of becoming experts in human health management, banking on the promise of revolutionizing healthcare. However, the reality is far from the ambitious goals set by these companies. Many consumer genetic testing products have proven to be short-lived, and 23andMe is no exception. Despite the initial enthusiasm from capital markets, 23andMe's market value has plummeted to around $300 million from $6.5 billion, highlighting a fundamental issue: consumer genetic testing, without addressing real medical problems, remains a limited consumer product.

Challenges in the Consumer Genetic Testing Industry:

The question arises: where does the future lie for consumer genetic testing companies? The success of a consumer genetic testing product hinges on its ability to provide comprehensive genetic information and assess the risk of genetic diseases, such as atrial fibrillation, coronary artery disease, and more. While there is a market for such products, the road to achieving the projected multi-billion-dollar scale in the global market is arduous. The waning enthusiasm of investors reflects the challenges faced by consumer genetic testing companies.

The Dilemma of 23andMe:

Within the realm of consumer genetic testing, 23andMe's product offerings are not particularly complex, with two core scenarios: ancestry tracing and health risk assessment. However, despite the initial hype, 23andMe's performance has been lackluster. In the 2022 fiscal year, the company generated only $200 million in revenue from consumer genetic testing, a figure that remained stagnant in 2023. This stark contrast with Ancestry, a competitor that has achieved significant success, can be attributed to Ancestry's long-standing user base and unique advantage in genealogy. In contrast, 23andMe heavily relies on digital advertising platforms like Facebook and Google to acquire users, yielding less than satisfactory results.

Consumer Product or Medical Solution?

The downfall of 23andMe underscores the fact that consumer genetic testing, without genuinely addressing medical issues, remains nothing more than a consumer product. Companies entering this field can only be seen as consumer-focused enterprises riding the wave of popularity. The overall demand for consumer genetic testing products is limited due to the lack of clear pain points they resolve. Diagnostic products, such as early screening for colorectal cancer, offer clear benefits, including performance comparable to colonoscopy, higher compliance rates, and affordability. On the other hand, consumer genetic testing products, beyond satisfying curiosity, fail to provide definitive conclusions about disease susceptibility and can only offer ambiguous answers regarding the possibility of increased risk. Studies suggest that consumer genetic testing products do not significantly contribute to future disease prevention for consumers. Consequently, the lack of a compelling demand limits user adoption and frequency of use, inhibiting the overall growth potential of the consumer genetic testing market.

The rise and fall of 23andMe, once a consumer genetic testing giant with a $6.5 billion market value, highlights the inherent limitations of consumer genetic testing as a healthcare solution. Without addressing genuine medical needs, consumer genetic testing products can only be seen as consumer goods with a restricted ceiling. The future of consumer genetic testing companies remains uncertain, and they must navigate the challenges of providing valuable medical solutions to thrive in this rapidly evolving industry.